SecBot SecBot
425 ·Filed Apr 22, 2026

GRTX

Galera Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001193125-26-168970
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor for SEC filings (Form S-4) with detailed proxy/prospectus information, as deal closes subject to shareholder and regulatory approvals. The low ownership stake for Galera shareholders suggests significant dilution.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
GRTX ▼ -16.50% at T+60d
NEUTRAL call -16.50% · α vs SPY -21.28% · entry $20.00 → $16.70
Entry = T+0 close
Apr 22, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.39%
$20.00
settled 6mo ago
T+5d
0.00%
call 0.00% · α -0.05%
$20.00
settled 6mo ago
T+20d
+1.00%
call +1.00% · α -3.22%
$20.20
settled 5mo ago
T+60d
-16.50%
call -16.50% · α -21.28%
$16.70
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Galera Therapeutics is being acquired by Obsidian Therapeutics in a merger, with a concurrent $350 million PIPE financing. The combined company will operate as Obsidian Therapeutics and list on Nasdaq under ticker OBX. This filing is a follow-up M&A communication reinforcing the deal's strategic rationale and timeline.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Obsidian Therapeutics is acquiring Galera Therapeutics via merger
  • Concurrent $350 million PIPE financing secured
  • Combined company to operate as Obsidian Therapeutics, ticker OBX on Nasdaq
  • Transaction expected to close by Q3 2026, subject to customary conditions
  • Pre-closing Obsidian stockholders to own ~53.2%, PIPE investors ~45%, Galera stockholders ~1.8%

Financial Impact

$350 million private investment

dilutioncash

Risk Factors

  • Deal may not close due to unmet conditions
  • Regulatory or shareholder approval delays
  • PIPE financing may not fully close

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-168970
Document: 0001193125-26-168970-index-headers.html0001193125-26-168970
Document: 0001193125-26-168970-index.html0001193125-26-168970
Document: 0001193125-26-168970.txt0001193125-26-168970
13 reports for GRTX
Performance horizon
50% Hit rate @ T+20 2 of 4 directional calls Went positive at some point 3 of 5 best @ T+20▲ +15.15%May 19, 2026
Filters
Rows
Reports for GRTX — sortable, filterable
TypeNow
Aug 10, 2026
11w ago
EFFECT
BEARISH ★ 6/10
—awaiting T+20——
Aug 4, 2026
11w ago
15-12G
NEUTRAL ★ 4/10
—awaiting T+20——
Aug 3, 2026
11w ago
8-K
BEARISH ★ 8/10
—awaiting T+20——
Jul 13, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$16.39awaiting T+20——
Jul 7, 2026
15w ago
8-K
BEARISH ★ 6/10
$17.80awaiting T+20——
May 21, 2026
22w ago
425
BULLISH ★ 7/10
$0.1000 $0.0910▼ −9.00%▼ −7.58%—
May 19, 2026
22w ago
8-K
BEARISH ★ 8/10
$0.1010 $0.0857▲ +15.15%▲ +15.89%—
Apr 22, 2026
26w ago
425
BULLISH ★ 7/10
$20.00 $20.20▲ +1.00%▼ −3.22%—
Apr 22, 2026
26w ago
425
NEUTRAL ★ 5/10
$20.00 $20.20▲ +1.00%▼ −3.22%—
Apr 14, 2026
27w ago
Press Release
BEARISH ★ 7/10
$0.0790 $0.1000▼ −26.58%▼ −20.29%—
Showing 10 of 13

US Market Status

Market Closed — Opens Tue (16h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 22, 2026